Apaziquone as an intravesical therapeutic agent for urothelial non-muscle-invasive bladder cancer

By Yutkin Vladimir   Chin Joseph  

Expert Opinion on Investigational Drugs, Vol. 21, Iss. 2, 2012-02 ,pp. : 251-260

Informa Healthcare

Access to resources Recommend Favorite

Perioperative chemotherapy for muscle-invasive bladder cancer: A population-based outcomes study

By Booth Christopher M.   Siemens D. Robert   Li Gavin   Peng Yingwei   Tannock Ian F.   Kong Weidong   Berman David M.   Mackillop William J.  

Cancer, Vol. 120, Iss. 11, 2014-06 ,pp. : 1630-1638

Blackwell Publishing

Access to resources Recommend Favorite

Contemporary cost-effectiveness analysis comparing sequential bacillus Calmette-Guerin and electromotive mitomycin versus bacillus Calmette-Guerin alone for patients with high-risk non–muscle-invasive bladder cancer

By Bachir Bassel G.   Dragomir Alice   Aprikian Armen G.   Tanguay Simon   Fairey Adrian   Kulkarni Girish S.   Breau Rodney H.   Black Peter C.   Kassouf Wassim  

Cancer, Vol. 120, Iss. 16, 2014-08 ,pp. : 2424-2431

Blackwell Publishing

Access to resources Recommend Favorite

Developing therapies for advanced bladder cancer

By Miyanaga Naoto   Akaza Hideyuki  

Expert Opinion on Investigational Drugs, Vol. 11, Iss. 1, 2002-01 ,pp. : 109-115

Informa Healthcare

Access to resources Recommend Favorite

Integrating Perioperative Chemotherapy into the Treatment of Muscle-Invasive Bladder Cancer: Strategy Versus Reality

By Donat S. Machele  

Journal of the National Comprehensive Cancer Network (JNCCN), Vol. 7, Iss. 1, 2009-01 ,pp. : 40-47

Cambridge Scholars Publishing in association with GSE Research

Access to resources Recommend Favorite